DNA methylation at diagnosis is associated with response to disease-modifying drugs in early rheumatoid arthritis
Aim: A proof-of-concept study to explore whether DNA methylation at first diagnosis is associated with response to disease-modifying antirheumatic drugs (DMARDs) in patients with early rheumatoid arthritis (RA). Patients & methods: DNA methylation was quantified in T-lymphocytes from 46 treatmen...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Published: |
Future Medicine
2016
|
| Online Access: | https://eprints.nottingham.ac.uk/40090/ |
| _version_ | 1848795982784888832 |
|---|---|
| author | Glossop, John R. Nixon, Nicola B. Emes, Richard D. Sim, Julius Packman, Jon C. Mattey, Derek L. Farrell, William E. Fryer, Anthony A. |
| author_facet | Glossop, John R. Nixon, Nicola B. Emes, Richard D. Sim, Julius Packman, Jon C. Mattey, Derek L. Farrell, William E. Fryer, Anthony A. |
| author_sort | Glossop, John R. |
| building | Nottingham Research Data Repository |
| collection | Online Access |
| description | Aim: A proof-of-concept study to explore whether DNA methylation at first diagnosis is associated with response to disease-modifying antirheumatic drugs (DMARDs) in patients with early rheumatoid arthritis (RA). Patients & methods: DNA methylation was quantified in T-lymphocytes from 46 treatment-naive patients using HumanMethylation450 BeadChips. Treatment response was determined in 6 months using the European League Against Rheumatism (EULAR) response criteria. Results: Initial filtering identified 21 cytosine-phosphate-guanines (CpGs) that were differentially methylated between responders and nonresponders. After conservative adjustment for multiple testing, six sites remained statistically significant, of which four showed high sensitivity and/or specificity (≥75%) for response to treatment. Moreover, methylation at two sites in combination was the strongest factor associated with response (80.0% sensitivity, 90.9% specificity, AUC 0.85). Conclusion: DNA methylation at diagnosis is associated with disease-modifying antirheumatic drug treatment response in early RA. |
| first_indexed | 2025-11-14T19:40:44Z |
| format | Article |
| id | nottingham-40090 |
| institution | University of Nottingham Malaysia Campus |
| institution_category | Local University |
| last_indexed | 2025-11-14T19:40:44Z |
| publishDate | 2016 |
| publisher | Future Medicine |
| recordtype | eprints |
| repository_type | Digital Repository |
| spelling | nottingham-400902020-05-04T18:19:56Z https://eprints.nottingham.ac.uk/40090/ DNA methylation at diagnosis is associated with response to disease-modifying drugs in early rheumatoid arthritis Glossop, John R. Nixon, Nicola B. Emes, Richard D. Sim, Julius Packman, Jon C. Mattey, Derek L. Farrell, William E. Fryer, Anthony A. Aim: A proof-of-concept study to explore whether DNA methylation at first diagnosis is associated with response to disease-modifying antirheumatic drugs (DMARDs) in patients with early rheumatoid arthritis (RA). Patients & methods: DNA methylation was quantified in T-lymphocytes from 46 treatment-naive patients using HumanMethylation450 BeadChips. Treatment response was determined in 6 months using the European League Against Rheumatism (EULAR) response criteria. Results: Initial filtering identified 21 cytosine-phosphate-guanines (CpGs) that were differentially methylated between responders and nonresponders. After conservative adjustment for multiple testing, six sites remained statistically significant, of which four showed high sensitivity and/or specificity (≥75%) for response to treatment. Moreover, methylation at two sites in combination was the strongest factor associated with response (80.0% sensitivity, 90.9% specificity, AUC 0.85). Conclusion: DNA methylation at diagnosis is associated with disease-modifying antirheumatic drug treatment response in early RA. Future Medicine 2016-11-25 Article PeerReviewed Glossop, John R., Nixon, Nicola B., Emes, Richard D., Sim, Julius, Packman, Jon C., Mattey, Derek L., Farrell, William E. and Fryer, Anthony A. (2016) DNA methylation at diagnosis is associated with response to disease-modifying drugs in early rheumatoid arthritis. Epigenomics . ISSN 1750-192X http://www.futuremedicine.com/doi/10.2217/epi-2016-0042 doi:10.2217/epi-2016-0042 doi:10.2217/epi-2016-0042 |
| spellingShingle | Glossop, John R. Nixon, Nicola B. Emes, Richard D. Sim, Julius Packman, Jon C. Mattey, Derek L. Farrell, William E. Fryer, Anthony A. DNA methylation at diagnosis is associated with response to disease-modifying drugs in early rheumatoid arthritis |
| title | DNA methylation at diagnosis is associated
with response to disease-modifying drugs in early rheumatoid arthritis |
| title_full | DNA methylation at diagnosis is associated
with response to disease-modifying drugs in early rheumatoid arthritis |
| title_fullStr | DNA methylation at diagnosis is associated
with response to disease-modifying drugs in early rheumatoid arthritis |
| title_full_unstemmed | DNA methylation at diagnosis is associated
with response to disease-modifying drugs in early rheumatoid arthritis |
| title_short | DNA methylation at diagnosis is associated
with response to disease-modifying drugs in early rheumatoid arthritis |
| title_sort | dna methylation at diagnosis is associated
with response to disease-modifying drugs in early rheumatoid arthritis |
| url | https://eprints.nottingham.ac.uk/40090/ https://eprints.nottingham.ac.uk/40090/ https://eprints.nottingham.ac.uk/40090/ |